Focused therapies are one cutting-edge method of treating breast cancer. Researchers at Mass General are demonstrating the effectiveness of novel anticancer treatments in breast development through a few clinical trials. A class of medications known as PI3 kinases (PI3K) regulates the mTOR protein, which is the target of the targeted therapy everolimus. In healthy cells, mTOR is involved in many different activities, such as cell proliferation and protein fusion. Instead of having a mastectomy, many women choose to have breast-preserving surgery, which involves removing only the cancer and a tiny amount of surrounding tissue.
Track 9.1: Neoadjuvant and Adjuvant Therapies
Track 9.2: Antibody-Drug Conjugates in Breast Cancer
Track 9.3: Emerging Targeted Therapy Approaches
Track 9.4: Combination Therapy Strategies
Track 9.5: Palliative Therapies for Advanced Breast Cancer
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
